Together with Eli Lilly and NIAID’s Vaccine Research Center, AbCellera’s Pandemic Prevention Platform team combined microfluidics, data science, machine learning, bioinformatics, and genomics to bring the first COVID-19 antibody to clinical trials in under 90 days, a process that typically requires three to six years. In June Eli Lilly began two Phase 1 clinical trials of COVID-19 antibodies isolated by AbCellera. “People have pushed themselves to the very limits of their endurance in this race against the virus,” says AbCellera head of R&D Ester Falconer.
collections
NewsletterCourses and LearningAdvertiseCurrent IssueFast Government
The future of innovation and technology in government for the greater good
Most Innovative Companies
Our annual guide to the businesses that matter the most
Most Creative People
Leaders who are shaping the future of business in creative ways
World Changing Ideas
New workplaces, new food sources, new medicine--even an entirely new economic system
Innovation By Design
Celebrating the best ideas in business
Follow us:
